-
1 Comment
GuiZhou SanLi Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 25.3% below its 200 day moving average.
From a valuation standpoint, the stock is 13.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10.9.
Based on the above factors, GuiZhou SanLi Pharmaceutical Co., Ltd gets an overall score of 0/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE1000040B4 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | None |
|---|---|
| Market Cap | 5B |
| PE Ratio | 19.11 |
| Beta | 0.82 |
| Dividend Yield | None |
GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular drugs, injury by fall medication, rehabilitation medicine, GI medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Anshun, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603439.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
